Targeting signal transduction in the discovery of antiproliferative drugs

Chemistry and Biology

Volumn 3, Issue 11, 1996, Pages 887-893

  Saltiel, Alan R ^a   Sawyer, Tomi K ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030294380     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(96)90177-5     Document Type: Review

References (29)

1. Levitski, A. & Gazit, A. (1695). Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1787.
2. Hunter, T. & Karin, M. (1992). The regulation of transcription by phosphorylation. Cell 70, 375-387.
3. Karp, J.E., & Broder, S. (1995). Molecular foundations of cancer: new targets for intervention. Nature Med. 1, 309-320.
4. Cohen, G.B., Ren, R. & Baltimore, D. (1995). Molecular binding domains in signal transduction proteins. Cell 80, 237-248.
5. Songyang, Z., et al., & Cantley, L.C. (1993). SH2 domains recognize specific phosphopeptide sequences. Cell 72, 767-778.
6. Feng, S., Chen, J.K., Yu, H., Simon, J.A., & Schreiber, S.L. (1994). Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science 266, 1241-1247.
7. Waksman, G., Shoelson, S.E., Pant, N., Cowburn, D., & Kuriyan, J., (1993). Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the comptexed and peptide-free forms. Cell 72, 779-790.
8. Plummer, M.S., et al., & Sawyer, T.K. (1996). Design of peptidomimetic ligands for the pp60(Src) SH2 domain. Bioorg. Med. Chem., in press.
9. Gilmer, T., et al., & Berman, J. (1994). Peptide inhibitors of Src SH3-SH2-phosphoprotein interactions. J. Biol. Chem. 269, 31711-31719.
10. Plummer, M.S., et al., & Sawyer, T.K. (1996). Hydrophobic D-amino acids in the design of peptide ligands for the pp60(Src) SH2 domain. Drug Design Discovery 13, 75-81.
11. Rodriguez, M., Crosby, R., Alligood, K., Gilmer, T., & Berman, J. (1995). Tripeptides as selective inhibitors of Src-SH2 phosphoprotein interactions. Lett. Peptide Sci. 2, 1-6.
12. Goudreau, N., et al., & Roques, B.P. (1994). NMR structure of the N-terminal SH3 domain of Grb2 and its complex with a proline-rich peptide from SOS. Nature Struct Biol. 1, 898-907.
13. Rahuel, J., et al., & Grutter, M.G. (1996). Structure basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nature Struct. Biol. 3, 686-689.
14. Boguski, M.S. & McCormick, F. (1993). Proteins regulating Ras and its relatives. Nature 366, 643-654.
15. Marshall, C.J. (1993). Protein prenylation: a mediator of protein-protein interactions. Science 259, 1865-1866.
16. Kohl, N.E., et al., & Gibbs, J.B. (1993). Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science 260, 1934-1937.
17. James, G.L., et al., & Marsters, Jr., J.C. (1993). Benzodiazepine peptidomimetics are potent inhibitors of Ras farnesylation in animal cells. Science 260, 1937-1942.
18. Hunt, J.T., et al., & Manne, V., J. (1996). Potent, ceil active, non-thiol tetrapeptide inhibitors of farnesyltransferase. Med. Chem. 39, 353-358.
19. Qian, Y., Blaskovich, M.A., Seong, C.-M., Vogt, A., Hamilton, A.D., & Sebti, S.M. (1994). Peptidomimetic inhibitors of p21Ras farnesyltransferase: hydrophobic functionalization leads to disruption of p21 Ras membrane association in whole cells. Bioorg. Med. Chem. Lett. 21, 2579-2584.
20. Lerner, et al., & Sebti, S.M. (1995). Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complsxes. J. Biol. Chem. 270, 26802-26806.
21. Zhang, X-F, et al., & Avruch, J. (1993). Normal and oncogenic p21Ras proteins bind to the amino terminal regulatory domain of c-Raf-1. Nature 364, 308-313.
22. Seger, R., et al., & Krebs, E.G. (1992). Human T-cell mitogen activated protein kinase kinases are related to yeast signal transduction kinases. J. Biol. Chem. 267, 25628-25631.
23. Boulton, T.G., et al., & Cobb, M.H. (1990). An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249, 64-67.
24. Kelly, K. (1993). Pac-1: a mitogen induced nuclear protein tyrosine phosphatase. Science 259, 1763-1766.
25. Pang, L., Zheng, C-F, Guan, K-L, & Saltiel, A.R. (1995), Nerve growth factor stimulates a novel protein kinase in PC-12 cells that phosphorylates and activates mitogen activated protein kinase kinase (MEK). Biochem. J. 307, 513-519.
26. Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J., & Saltiel, A.R. (1995). A synthetic inhibitor of the mitogen activated protein kinase cascade. Proc. Natl, Acad. Sci. USA 92, 7686-7689.
27. Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T., & Sattiel, A.R. (1995). PD98059 is a specific inhibitor of the activation of mitogen activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494.
28. Lazar, D.F., et al., & Saltiel, A.R. (1995). Mitogen activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin, J. Biol. Chem. 270, 20801-20807.
29. Waters, S.S., et al., & Pessin, J.E. (1995). Desensitization of Ras activation by a feedback disassociation of the SOS-Grb2 complex. J. Biol. Chem. 270, 20883-20886.